Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.45 |
| ▸ | USP7 | Q93009 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15667518 | 0.85 | ESR2 (0.44) | ESR1ESR2FGFR1DRD1AR | |
| SCHEMBL15688326 | 0.79 | ESR1 (0.44) | ESR1ESR2DRD1 | |
| SCHEMBL17178291 | 0.79 | AMY1A (0.45) | USP7DRD1 | |
| SCHEMBL17200350 | 0.78 | ESR2 (0.43) | ESR1ESR2USP7DRD1AR | |
| SCHEMBL17174358 | 0.76 | DRD1 (0.41) | DRD1 | |
| SCHEMBL17200352 | 0.73 | ESR1 (0.47) | ESR1ESR2USP7FGFR1FGFR2 | |
| SCHEMBL19390564 | 0.73 | SENP1 (0.45) | ESR1ESR2USP7 | |
| SCHEMBL19390579 | 0.70 | MEN1 (0.41) | ESR1ESR2FGFR1 | |
| SCHEMBL16982140 | 0.69 | ESR1 (0.57) | ESR1ESR2FGFR1FGFR2AR | |
| SCHEMBL29557461 | 0.69 | ESR1 (0.74) | ESR1ESR2FGFR1FGFR2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3134087-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2020-03-18 | — | — | EP | disclosed |
| EP-2917219-B1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER (US) | 2017-09-27 | — | — | EP | disclosed |
| US-9688698-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2017-06-27 | — | — | US | disclosed |
| EP-3134087-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2017-03-01 | — | — | EP | disclosed |
| WO-2015162515-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307522-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, DRD4 | ESR1 473/4885ESR2 1327/4885USP7 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.